Acute Myeloid Leukemia, AML
Conditions
Keywords
AML, Acute Myeloid Leukemia
Brief summary
This research study is evaluating whether a psychological mobile application (app), is efficacious in reducing anxiety and depression symptoms and improving quality of life for patients diagnosed with acute myeloid leukemia (AML) compared to a physical health promotion app.
Detailed description
Patients with a new diagnosis of AML often confront a sudden and life-threatening diagnosis, requiring an immediate disruption of their life and an urgent 4-6 week hospitalization to initiate intensive chemotherapy. During this hospitalization, they endure substantial physical symptoms due to the side-effects of intensive chemotherapy, which negatively impacts their quality of life. Patients with AML also experience significant psychological distress as they struggle with the abrupt onset of illness, uncertainty regarding their prognosis, physical and social isolation during their hospitalization, and complete loss of independence. From our prior studies, we learnt that the use of DREAMLAND, a psychological mobile app, was feasible to integrate in the care of patients with AML receiving intensive chemotherapy and has promising efficacy for improving patients' physical and psychological symptoms and their quality of life. In this project, the study doctors want to compare the effectiveness of DREAMLAND versus CERENA in improving the patient experience when diagnosed with AML. CERENA is a mobile app that provides medical information about how to best take care of one´s health. Using this research, the study doctors hope to find out the best way to help patients cope with the diagnosis and treatment for AML. The study will use questionnaires to measure patient's quality of life, physical symptoms, mood, and the participant sense of control over their situation. Study questionnaires will be completed in the hospital or clinic. The participants will also have the option of completing these questionnaires remotely through a secure web link or through a mailed paper copy. Blue Note Therapeutics, Inc. is supporting this research study by providing funding. Blue Note Therapeutics is a digital health technology company that focuses on the health needs of patients with a cancer diagnosis.
Interventions
BEHAVIORALDREAMLAND
DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on: 1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance. 2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support. 3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty. 4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care. Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete. Other names BNT200
BEHAVIORALCERENA
CERENA is a self-administered physical health app that includes 4 modules focused, focused on: 1. Education about general wellness. 2. Nutrition. 3. Exercise. 4. Cancer prevention. Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete.
Sponsors
Blue Note Therapeutics
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Caregiver, Investigator)
Masking description
This is a double-blind multi-site randomized efficacy trial of two mobile apps: DreAMLand versus CERENA in 180 patients with AML. Patients will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DreAMLand versus CERENA. The study investigators and clinicians caring for these patients will be blinded to the study group assignment.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hospitalized patients (aged 18 years or older) with a new diagnosis of AML * Receiving treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or b) a similar intensive regimen requiring prolonged 3-6-week hospitalization * Ability to comprehend and speak English as the mobile apps are only available in English
Exclusion criteria
* Patients with a diagnosis of acute promyelocytic leukemia * Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anxiety Symptoms | Day 20 | Compare anxiety symptoms between participants receiving DREAMLAND versus CERENA as measured by the Hospital Anxiety and Depression Scale (HADS)-anxiety subscale over 20 days. Higher scores on the HADS anxiety subscale (range 0-21) indicate greater anxiety symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depression Symptoms | Up to Day 90 | Compare depression symptoms between participants receiving DREAMLAND versus CERENA as measured by the Hospital Anxiety and Depression Scale (HADS)-depression subscale and the Patient Health Questionnaire-9 (PHQ-9) over 90 days. Higher scores on the HADS-depression subscale (range 0-21) indicate greater depression symptoms. Higher scores on the PHQ-9 (range 0-27) indicate greater depression symptoms. |
| Quality of Life in Patients with Leukemia | Up to Day 90 | Compare quality of life between participants receiving DREAMLAND versus CERENA as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) over 90 days. Higher scores on FACT-Leukemia (range 0-176) indicate better quality of life. |
| Symptom Burden | Up to Day 90 | Compare symptom burden between participants receiving DREAMLAND versus CERENA as measured by the Edmonton Symptom Assessment Scale-Revised (ESAS-R) over 90 days. Higher scores on the ESAS-R (range 0-100) indicate worse symptom burden. |
| Post-Traumatic Stress Disorder (PTSD) Symptoms | Up to Day 90 | Compare PTSD symptoms between participants receiving DREAMLAND versus CERENA as measured by the PTSD Checklist-Civilian Version over 90 days. Higher scores on the PTSD Checklist-Civilian Version (range 17-85) indicate greater PTSD symptoms. |
| Anxiety Symptoms | Up to Day 90 | Compare anxiety symptoms between participants receiving DREAMLAND versus CERENA as measured by the Hospital Anxiety and Depression Scale (HADS)-anxiety subscale over 90 days. Higher scores on the HADS-anxiety subscale (range 0-21) indicate greater anxiety symptoms. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Health care utilization | Up to 6 months | to explore differences in hospitalizations, emergency department visits, and days spent in the hospital between participants receiving DREAMLAND versus CERENA as measured based on data obtained from the Electronic Health Record up to 6 months |
| Self-efficacy | Up to Day 90 | Compare self-efficacy between participants receiving DREAMLAND versus CERENA as measured by the Cancer Self-Efficacy Scale (CASE) over 90 days. Higher scores on the CASE (range 0-170) indicate greater self-efficacy. |
| Coping | Up to Day 90 | Compare coping between participants receiving DREAMLAND versus CERENA as measured by the Measure of Current Status - Part A (MOCS-A) over 90 days. Higher scores on the MOCS-A (range 0-52) indicate better coping. |
Countries
United States
Outcome results
None listed